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Abstract 
Objective.  Genetic activation of the insulin signal-transducing kinase AKT2 causes syndromic 
hypoketotic hypoglycaemia without elevated insulin.  Mosaic activating mutations in class 1A 
phospatidylinositol-3-kinase (PI3K), upstream from AKT2 in insulin signalling, are known to 
cause segmental overgrowth, but the metabolic consequences have not been systematically 
reported.  We assess the metabolic phenotype of 22 patients with mosaic activating mutations 
affecting PI3K, thereby providing new insight into the metabolic function of this complex node in 
insulin signal transduction. 
Methods. Three patients with megalencephaly, diffuse asymmetric overgrowth, hypoketotic, 
hypoinsulinaemic hypoglycaemia and no AKT2 mutation underwent further genetic, clinical, and 
metabolic investigation.  Signalling in dermal fibroblasts from one patient, and efficacy of the 
mTOR inhibitor Sirolimus on pathway activation was examined. Finally, the metabolic profile of a 
cohort of 19 further patients with mosaic activating mutations in PI3K was further assessed. 
Results.  In the first three patients mosaic mutations in PIK3CA (p.Gly118Asp or p.Glu726Lys) or 
PIK3R2 (p.Gly373Arg) were found..  In different tissue samples available from one patient, the 
PIK3CA p.Glu726Lys mutation was present at burdens from 24% to 42%, with the highest level in 
the liver. Dermal fibroblasts showed increased basal AKT phosphorylation which was potently 
suppressed by Sirolimus.  Nineteen further patients with mosaic mutations in PIK3CA had neither 
clinical nor biochemical evidence of hypoglycaemia.  
Conclusions.  Mosaic mutations activating class 1A PI3K cause severe non-ketotic hypoglycaemia 
in a subset of patients, with the metabolic phenotype presumably related to the extent of mosaicism 
within the liver.  mTOR or PI3K inhibitors offer the prospect for future therapy.  
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Introduction 
Transient neonatal hypoglycaemia is common, often precipitated by inadequate deposition 
of energy stores in utero and/or perinatal stress.  In contrast, persisting hypoglycaemia is often 
caused by a genetic disorder, and may be insulin-dependent or insulin-independent (1, 2, 3).  The 
former is usually caused by congenital hyperinsulinism (CHI), or occasionally extreme insulin 
resistance (4).  CHI-related hypoglycaemia features suppressed plasma ketones and free fatty acids 
but detectable plasma insulin, while glucagon stimulation characteristically increases blood 
glucose by greater than 30 mg/dl (5).   Carbohydrate requirement to maintain euglycaemia in CHI 
is high, with intravenous glucose infusion rates usually exceeding 8 mg/kg/min in neonates and 
infants (2).  Non-insulin-dependent hypoglycaemia may be caused by inherited metabolic diseases 
including glycogen storage or fatty acid oxidation disorders (6, 7). 
We previously described a syndromic form of hypoglycaemia whose metabolic profile 
resembles CHI, yet in which neither insulin nor insulin-like molecules can be detected during 
hypoglycaemia (8).  It is caused by the p.Glu17Lys mutation in the kinase AKT2, a critical 
mediator of insulin action (9).  This mutation partly uncouples AKT2 activation from insulin-
stimulated phosphatidylinositol-3-kinase (PI3K) activity by permitting binding of AKT2 to the 
PI3K substrate PIP2 in addition to its product phosphatidylinositol (3,4,5)-trisphosphate (PIP3) 
(Figure 1) (10).  This results in low-level cellular responses mimicking the presence of insulin. 
Activating mutations in other components of the PI3K/AKT pathway are common in cancer 
(11, 12), and in isolation, in mosaic form, cause segmental overgrowth (13, 14, 15).  The most 
commonly mutated gene is PIK3CA, encoding the p110α catalytic subunit of PI3K (13). Mutations 
in other genes including PIK3R2, encoding the p85β regulatory subunit of PI3K, are also described 
(16).  PIK3CA-associated Overgrowth in mosaic syndromes is known to affect venous and 
lymphatic vessels, adipose tissue, bone, muscle and neural tissue.  Notably, the timing and site of 
the mutation gives rise to different patterns within the body, ranging from very specific 
localized/focal forms to diffuse manifestations involving multiple tissues.  Additionally, the 
strength of genetic activation may further determine the severity of tissue-specific symptoms, 
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resulting in pronounced phenotypic variability of these disorders, potentially also affecting 
metabolic and/or endocrine tissues.  PIK3R2 mutations lead to Megalencephaly-Polymicrogyria-
Polydactyly-Hydrocephalus (MPPH) syndrome which is predominantly characterised by brain 
overgrowth and neurological abnormalities; mutations are often germline rather than mosaic.  To 
date, although PIK3CA has been proven in numerous genetic and pharmacological studies to be 
critical for the metabolic effects exerted by insulin, and despite scattered mentions of 
hypoglycaemia in MCAP (17, 18), the metabolic phenotype has not been examined in detail. 
We now describe three patients with early-onset, severe, non-ketotic hypoglycaemia 
associated with segmental overgrowth and activating mutations in PIK3CA or PIK3R2, and assess 
the PI3K pathway dysregulation in vitro in patients’ fibroblasts. Furthermore, we systematically 
survey the metabolic profile of a cohort of patients with mosaic PI3K activation ascertained 
through segmental overgrowth. 
Subjects and Methods 
Cohort Studied and Ethical Approval 
Informed consent was obtained from all participants, research was approved by relevant 
research ethics committees, and the study was performed in accordance with the Declaration of 
Helsinki.  For the cohort analysis, all patients with mosaic activating PIK3CA mutations from a 
study of segmental overgrowth for whom metabolic data were available were also assessed, 
encompassing volunteers with diagnoses of CLOVES (Congenital lipomatous overgrowth with 
vascular, epidermal, and skeletal anomalies) syndrome (OMIM #612918) (19), Klippel-Trenaunay 
(KT) syndrome (OMIM #149000) (20), Fibroadipose hyperplasia (13), macrodactyly or primary 
muscle overgrowth (21), or Megalencephaly-Capillary Malformation (MCAP) (OMIM #602501) 
(22).  Biochemical evaluations were performed in accredited diagnostic laboratories.  
Genetic studies 
For Sanger sequencing exons and flanking regions were PCR-amplified before sequencing 
using ABI’s BigDye Terminator Mix, purification using AgenCount AMPure Beads, capillary 
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electrophoresis and analysis using Sequencher software (GeneCodes).  Exome-wide sequencing for 
P1 and parents was performed and analysed as previously described (23).  PIK3CA p.Glu726Lys 
mutation burden was determined by custom-designed fluorescence-based restriction fragment 
assay (as described in Supplementary Online Material).  P3 salivary DNA was sequenced using a 
custom panel of overgrowth-related genes on an Illumina MiSeq platform with preceding target 
enrichment.  Further method and details are described in the Supplementary Online Material. 
Cellular studies 
Dermal fibroblasts were cultured from punch biopsies and maintained in DMEM 
supplemented with 10 % Foetal Bovine Serum containing 100 U/ml Penicillin, 100 µg/ml 
Streptomycin and 4 mM L-Glutamine (all Sigma).  For serum starvation, FBS was substituted by 
0.5 % Bovine Serum Albumin (Sigma).  For signalling studies fibroblasts were grown to 
confluence and washed twice with PBS before serum starvation for 24 hours.  Sirolimus (Sigma) 
was diluted in DMSO to 10 µM.  Cells were pre-treated with Sirolimus or DMSO for 48 hours 
prior to continued treatment during serum starvation.  Cells were frozen in liquid nitrogen and 
stored at -80 °C until processing. 
AKT phosphorylation was determined using ELISAs for pThr308/309 and pSer473/474 
(eBiosciences #85-86044 & #85-86042) according to manufacturer’s instructions. Protein 
quantification was performed by DC Protein assay (BioRad).  For immunoblotting lysates were 
resolved by electrophoresis on 8 % Bis-Tris gels (NuPage, Thermo Fisher) before transfer onto 
nitrocellulose membranes using the iBlot system (Life Technologies).  Membranes were blocked in 
4 % BSA/TBST prior to primary antibody exposure for 16 hours.  Following addition of secondary 
antibodies, blots were imaged on a BioRad ChemiDoc.  The following antibodies were used: anti-
calnexin (AbCam #22595), anti-AKT(1/2/3) (CST #9272), anti-rabbit HRP conjugate (CST 
#7074).  ImageLab software (BioRad) was used to determine band intensity. 
Statistical analysis 
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Statistical analysis was undertaken using GraphPad Prism v.6.  Log transformation was 
performed prior to analysis as the D'Agostino-Pearson test showed non-normal distribution of 
results.  One-way analysis of variance (ANOVA) was undertaken followed by Dunnett’s test for 
comparison of patient against control cells.   
Results 
Clinical Histories 
Clinical features of patients 1-3 are summarised in Table 1.  Patient 1 (P1) was born at 34 
weeks to healthy, non-consanguineous white German parents after polyhydramnios and 
macrocephaly were noted in utero.  Her birthweight was 3230 g (+2.0 SD), length 52 cm (+1.5 
SD), and head circumference 37.5 cm (+2.3 SD).  Generalised muscle hypotonia, hyperaemia of 
the face, a dorsal haemangioma and dysmorphic features including diastasis recti, syndactyly, short 
limbs and a “chubby” appearance were noted at birth (Figure 2A&B).   
Recurrent hypoglycaemia was observed on day one.  On repeated evaluations, suppressed 
ketones, undetectable insulin, and low free fatty acids were found concomitantly with blood 
glucose below 2,5 mmol/l.  Growth hormone and cortisol rose in response to hypoglycaemia, while 
plasma amino acids, urinary organic acids and acylcarnitine profile were normal.  There was 
neither clinical nor biochemical evidence of glycogen storage diseases.  Intravenous glucose 
requirement to maintain euglycaemia in the neonatal period was consistently below 8 mg/kg/min.  
Fasting tolerance in infancy peaked at 3 hours before hypoglycaemia occurred, and management 
was based on frequent starch-enriched meals.  Within the first months of life poor oral intake led to 
placement of a percutaneous gastric (PEG) tube.  
Diazoxide at up to 7.5 mg/kg/d for 2 weeks at the age of 1 year produced no benefit.  
Octreotide was tried once (5 µg/kg s.c.), and increased blood glucose from 1.8 to 5.0 mmol/l within 
30 minutes, but was discontinued due to flushing.  Glucagon (1 mg s.c.) elicited a modest glucose 
response during hypoglycaemia (1.9 to 2.2 mmol/l within 30 minutes), however this was at a time 
of hepatopathy, evidenced by elevated liver transaminases (ALT 99 U/l, AST 183 U/l) and γGT 
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(762 U/l).  Liver biopsy, described in detail in Supplementary Online Material, did not reveal any 
evidence of steatosis or glycogen storage disease, but showed evidence of ductular proliferation 
without cholestasis or primary duct injury, reminiscent of the response to acute hepatocyte injury 
(Supplementary Figure S1).  20 mg/m2/day methylprednisolone followed by 23 mg/m2/day 
hydrocortisone slightly improved blood glucose but rapidly increased body weight and reduced 
growth velocity, leading to cessation after 3 months.  Subsequent management was with starch-
enriched feeds during the day and PEG feeding with maltodextrin overnight.  During nocturnal 
enteral feeding glucose requirements were around 2-4 mg/kg/min, between 1 and 5 years of age, 
and euglycemic clamp studies demonstrated a requirement for 2.4 mg glucose/kg/min to maintain 
blood glucose between 4.0-4.7 mmol/l at the age of 4 years.  At 4 years old she still required 
continuous overnight feeding, and well documented episodes of profound nocturnal 
hypoglycaemia occurred following accidental PEG displacement. 
Body length was maintained around -3 SD throughout childhood except during 
glucocorticoid treatment.  Body weight was between 0 to +1.3 SD, with a weight:length ratio 
above the 97th percentile.  Head circumference was between +3.0 and +4.0 SD (Figure 2C).  IGF1 
and IGFBP3 were low on repeated evaluations, but growth hormone (GH) response to arginine 
stimulation testing at the age of 15 months was normal (13.8 µg/l within 30 minutes).  An IGF1 
generation test (GH 33 µg/kg s.c. daily for 7 days) only increased IGF1 from 25 to 56 µg/l.  
Decreased TSH (0.84 mU/l, reference: 0.6-5.5 mU/l), and free T4 (15.7 pmol/l, reference 10-20 
pmol/l) were observed at 10 months.  1.8 µg/kg/d levothyroxine normalised fT4, with TSH 
remaining low.   
Additional problems included severe developmental delay and an obstructing Arnold-Chiari 
malformation requiring ventriculoperitoneal shunting at 5 months.  Recurrent airway infections 
required intensive respiratory support/artificial ventilation, however no formal assessment for 
immunodeficiency was undertaken.  Aged 3.7 years focal seizures independent from hypoglycemia 
developed.  Levetiracetam was commenced and titrated to 50 mg/kg/d at 5 years, when the patient 
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died following cardiorespiratory arrest during an upper airway infection.  There was no evidence of 
hypoglycaemia nor Arnold-Chiari decompensation.  The cause of death remains unknown.  
Patient 2 (P2) was born to non-consanguineous white Spanish parents at term after 
polyhydramnios and macrocephaly were identified in utero.  His birthweight was 4340 g (+6.8 
S.D.), length 53 cm (+1.66 S.D.) and head circumference 41 cm (+5.14 S.D.).  Cutis marmorata, 
lower lip hemangioma, cutaneous lymphatic malformations, and syndactyly in hands and feet were 
noted at birth.  Imaging revealed polymicrogyria, hydrocephalus, and an Arnold Chiari 
malformation requiring ventriculoperitoneal shunting at 12 months.  Motor development was 
delayed with marked muscle hypotonia at 10 months.  Generalized seizures developed at 1 year, 
treated with sodium valproate.  Liver ultrasonography at 14 months was normal. 
Hypoglycaemia was first noted at 4 days and later shown repeatedly to be hypoketotic and 
hypoinsulinaemic.  Free fatty acid and acylcarnitine profiling were normal, and glucagon 
stimulation demonstrated preserved, mobilisable glycogen stores (Table 2).  A reduced GH 
response to hypoglycaemia was demonstrated at one month old, accompanied by reduced IGF1 
(<25 ng/ml) and IGFBP3 (10th percentile) concentrations.  Diazoxide had no beneficial effect, and 
management was with regular starch-enriched meals and overnight percutaneous feeding.  The 
glucose infusion rate used to maintain euglycaemia was 13 mg/kg/min, but no formal 
determination of the minimum requirement was undertaken.  By 10 months, obesity had developed 
(weight 11.3 kg (>2.5 SD)). At 12 months, percutaneous feeding could be stopped, however 
regular carbohydrate-enriched meals continue to be required.  Despite persistently low plasma 
IGF1 and IGFBP3 growth velocity was preserved, with height remaining between the 50th and 75th 
percentiles at 2.8 years (target height 20th percentile). 
Patient 3 (P3) was born to non-consanguineous English parents at 42 weeks gestation 
following pre-natal diagnosis of hydrocephalus and macrocephaly.  His birthweight was 3,980 g 
(+0.33 SD).  On the first day of life he had a generalised seizure with undetectable plasma glucose.  
Because of recurring hypoglycaemia in the first week of life, 13 mg/kg/min intravenous glucose 
was used to maintain euglycaemia without titration to the lowest dose required.  Repeated 
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evaluations over ensuing months showed fasting hypoglycaemia with suppressed ketones, 
undetectable insulin and low but detectable C peptide levels  (Table 2).  Short synacthen testing, 
thyroid function, and a genetic screen for congenital hyperinsulinism were normal or negative.  
Diazoxide was trialled with no discernible benefit, and 4-hourly carbohydrate-enriched feeds were 
required to maintain euglycaemia.   
At 3 months macrocephaly was noted (head circumference 47 cm (+5.49 SD)) with a coarse 
facial appearance, hypertrichosis, and broad digits with soft palms and soles with deep creases and 
excess skin (Figure 2D-F).  Imaging showed hydrocephalus and bilateral presylvian 
polymicrogyria requiring insertion of a ventriculoperitoneal shunt.  A clinical diagnosis of MPPH 
(OMIM #603387 & #615937) was made.  At 2.3 years, weight was 14.7 kg (+1.23 SD), height 
95.2 cm (+1.72 SD) and head circumference 53.6 cm (+3.62 SD).  Partial seizures are well 
controlled on phenobarbital but he is severely intellectually delayed with no speech and inability to 
sit unaided. 
Genetic Diagnosis 
AKT2 was wildtype in lymphocyte DNA from P1, so the patient and parents underwent 
whole exome sequencing.  5 non-synonymous candidate pathogenic variants were identified with a 
frequency <0.01 in control databases and a posterior probability of de novo inheritance >0.8 
(supplementary Table 1) including a single nucleotide substitution (c.2176 G>A; p.Glu726Lys) in 
PIK3CA (NM_006218.3), encoding the p110α catalytic subunit of PI3K.  This variant was called 
in 26 of 103 reads, suggesting somatic mosaicism.  Sanger sequencing identified the mutation in 
multiple tissues (Figure 3A), while restriction fragment length polymorphism assay showed 
mutation burdens from 24 % (saliva) to 42 % (liver).   Dermal fibroblast DNA from P2 was 
screened for mutations in PIK3CA using Sanger sequencing, revealing the PIK3CA c.365 G>A 
mutation (p.Gly118Asp).  This was absent from lymphocyte DNA.  Both PIK3CA mutations have 
previously been described (OMIM #602501) (16, 24).  DNA from a buccal swab of patient P3 was 
screened for overgrowth-associated mutations using an Illumina MiSeq Panel (Supplementary 
Online Materials Table 2).  A heterozygous c.1117G>A (p.Gly373Arg) mutation was identified in 
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PIK3R2 (NM_005027.3), encoding the p85β regulatory subunit of class 1A PI3K.  p.Gly373Arg is 
the most common mutation in PIK3R2 associated with MPPH type 1 (OMIM #603387) (16).   The 
mutation was identified at a mutation burden of 50%, and this was confirmed independently in a 
diagnostic laboratory in lymphocyte DNA, also at 50%, consistent with a constitutional mutation.  
No parental DNA was available for testing.  The locations of all 3 mutations in their respective 
proteins are schematised in Figure 3B. 
Cellular Studies 
Dermal fibroblasts of P1 were cultured and shown to harbour a mutation burden of 33 %, 
consistent with 66 % of the cells carrying a heterozygous mutation at passage 4 (Figure 3A).  They 
showed a small, significant increase in basal phosphorylation of AKT at Threonine 308/309 and 
Serine 473/474, as in cells expressing AKT2 p.Glu17Lys or the overgrowth-related PIK3CA 
p.His1047Leu (Figure 4A-C).  By passage 6 this was no longer seen in cells from P1, likely due to 
progressive decline in mutation burden.  72 hours exposure to Sirolimus, a dual 
mTORC1/mTORC2 inhibitor, did suppress basal hyperphosphorylation of AKT at Serine 473/474 
(the target site of the upstream kinase mTORC2) in early passage cells from another patient 
carrying the same PIK3CA p.Glu726Lys mutation (P21) (Figure 4D), however, or cells expressing 
PIK3CA p.His1047Leu (Figure 4E).   
Metabolic Assessment of a wider PI3K-related overgrowth spectrum (PROS) Cohort 
To profile the wider metabolic consequences of mosaic activation of PI3K, a further 19 
patients with mosaic activating PIK3CA mutations were assessed, as summarised in Table 3.  All 
patients had clinical disorders encompassed by the PIK3CA-Related Overgrowth Spectrum (PROS) 
(15), and were subdivided into those with severe, localised overgrowth, and those with more 
diffuse overgrowth including the brain, similar to patients 1-3.  One further patient in this group 
had the same p.Glu726Lys variant as P1 and one had the p.Gly118Asp variant seen in P2. 
None of the PROS patients had fasting hypoglycaemia, however three patients with MCAP 
had low or undetectable plasma insulin concentrations with normal or low-normal fasting glucose 
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(P19, P20, P22; Table 3).  One of these patients P19 had previously had hypoglycaemia during an 
episode of diarrhoea and vomiting.  Five of the eight patients with MCAP, including all three with 
low fasting insulin levels, had low IGF1 concentrations.  Two patients with more extensive 
overgrowth (P6 and P9) had hyperinsulinemia consistent with insulin resistance. 
Oral glucose tolerance tests (OGTT) were completed for thirteen patients, five with MCAP.  
As shown in Supplementary Table 3 and Supplementary Figure 2, glucose and insulin were within 
normal ranges.  Finally, given the large pathological expansion of specific adipose depots in many 
patients with focal severe PROS, and the interest in distinct physiological properties and secreted 
adipokine profiles of these depots, adipokine levels relative to whole body fat mass were compared 
between adults in the PROS group and a large control dataset (Supplementary Figure 3).  However, 
adipokine levels were similar to those in the control population in the large majority of PROS 
patients including those with extreme focal fat mass (P7, P8), arguing that the adipokine profiles 
are not distinct in different forms of PROS.  Two exceptions were P4, a patient with CLOVES who 
had a disproportionately high adiponectin concentration, and P20, a patient with CLOVES who 
had a disproportionately low leptin concentration. 
Discussion  
“PI3K” here denotes a group of enzymes composed of one of three catalytic subunits 
(p110α, β or δ) and one of five regulatory subunits (p85α, p55α, p50α, p85β, or p55γ) (25).  PI3K 
generates PIP3 in response to insulin receptor activation, leading in turn to AKT/PKB activation.  
Genetic and pharmacological evidence has established that the catalytic p110α subunit, encoded by 
PIK3CA, is critical for the glucose-lowering by insulin, while AKT2 is the “metabolic” AKT 
isoform (26).  The only example to date of hypoketotic hypoglycaemia due to a mutation activating 
insulin signalling is a de novo activating mutation in AKT2 (27) that has been described in five 
patients.  Activation of other components of this pathway, such as PI3K, would be anticipated to 
cause a similar metabolic profile, however given the pleiotropic growth-promoting actions of 
PI3K, the associated syndrome would be expected to be more complex.  Mosaic genetic activation 
of PI3K has recently been described in a wide range of segmental overgrowth disorders with 
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overlapping features (13), (28).  Seven patients with PIK3CA mutations, overgrowth and infantile 
hypoglycaemia were described while this work was underway (18), but no further metabolic 
characterisation was undertaken. 
We describe three patients with megalencephalic PI3K-related overgrowth who had severe, 
likely non insulin-dependent hypoketotic hypoglycaemia, similar to that caused by activating AKT2 
mutations, persisting to at least 2 years old in all cases.  This affected only a subset of patients with 
PI3K-related overgrowth, likely due to the predominantly mosaic nature of the condition.  This 
mosaicism, with only some cells and tissues affected, complicates efforts to distinguish among 
several possible mechanisms underlying hypoglycaemia.  The simplest explanation is that tonic 
activity of hepatic PI3K leads to inappropriate suppression of hepatic glycogenolysis and 
gluconeogenesis in the postabsorptive state.  Most of the liver would have to be affected to exert a 
significant effect. A liver biopsy from P1 presented the opportunity to examine liver in one patient 
with PIK3CA-related hypoglycaemia. It showed a mutation burden of 42 %, corresponding to 84 % 
of cells bearing a  heterozygous mutation, however neither glycogenosis nor steatosis were seen, 
while prominent ductular reaction without cholestasis or primary duct injury was reminiscent of 
the response to severe and acute hepatocyte injury (29).  Without knowing which cells harboured 
the PIK3CA mutation, no more precise correlation was possible between the abnormal histology 
and the mutation.  If liver-autonomous failure to derepress glycogenolysis/gluconeogenesis were 
the major abnormality explaining PROS-related hypoglycaemia, then only a small glucose 
requirement to maintain euglycaemia would be expected, as reported for patients with activating 
AKT2 mutations. (27)  This was confirmed for P1 in this report, however infusion rates in P2 and 
P3 were reported to be high.  Whether glucose infusions were titrated to the lowest possible rate to 
maintain euglycaemia was unclear, however.     
PI3K-related hypoglycaemia may alternatively reflect suppression of adipose lipolysis, 
which provides energy and gluconeogenic substrates to fasting hepatocytes (30, 31).  This was 
shown by the lack of an adequate rise of free fatty acids in P1 during hypoglycaemia (Table 2).   
Fasting free fatty acid levels in the PROS cohort were not studied, however in two patients with 
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genetic AKT2 activation we observed correlation of free fatty acid suppression with fasting 
hypoglycaemia (manuscript under review).  Although increased PI3K-mediated, GLUT4-
dependent glucose uptake into skeletal muscle, and adipose tissue could also cause hypoglycaemia, 
patients with severe local adipose or muscle overgrowth due to strongly activating PIK3CA 
mutations, but with no liver involvement, exhibited neither spontaneous hypoglycaemia nor 
hypoinsulinaemia.  This argues that regional adipose tissue or muscle PI3K-mediated glucose 
uptake either does not occur, or is insufficient to produce hypoglycaemia.  
Finally, aberrant activity of PI3K in the brain may also play a role: low IGF1 levels in 63 % 
of the MCAP patients suggest dysfunctional growth hormone (GH) secretion or action.  This may 
reflect tonically active PI3K in the hypothalamus and/or the pituitary, mimicking IGF1 action and 
erroneously activating negative feedback inhibition of GH releasing hormone or GH release.  In 
contrast, stimulation of GH secretion on provocative testing may yield normal results, as shown in 
P1, suggesting that suppressed basal secretion may be overridden.  The central hypothyroidism in 
P2, and in three previously described MCAP patients (18), and the modest GH and cortisol 
responses to hypoglycaemia suggest that hypothalamic-pituitary function may show wider 
perturbation.  Attenuated neuroendocrine counterregulatory responses to hypoglycaemia are a 
plausible explanation for the GH and cortisol responses, however this cannot be proven, and 
studies of further affected patients will be required to elucidate whether abnormality of regulation, 
a subtle developmental disorder of the hypothalamus/pituitary or both are seen in MCAP caused by 
PI3K activation. Evidence that different adipose depots show distinct profiles of adipokine 
secretion (32, 33), raised the possibility that pathological expansion of only some adipose depots 
(e.g. legs vs upper body) would correspond to a distinct pattern of circulating adipokines.  In 
general, we found this not to be the case, with the large majority of patients showing a similar 
relationship between adipokine concentrations and whole body adipose tissue mass to that seen in 
the general population.  Two outliers were found with perturbed adiponectin or leptin levels, 
however the explanation was not immediately clear, and wider investigation may be warranted.  
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Importantly, our findings suggest that mTOR inhibitors such as Sirolimus may have 
therapeutic benefit instead of, or in addition to, nutritional therapies including percutaneous 
overnight feeding.  Although Sirolimus is primarily an mTORC1 inhibitor, prolonged use 
sequesters components of the mTORC2 complex (34), which acts upstream from AKT in insulin 
signalling.  Our findings suggest that Sirolimus at very low doses (1.1-2.2 ng/ml) may be 
sufficient, unlike the high doses used in hyperinsulinism (5-15 ng/ml) (35).  In future, low doses of 
more specific Class 1A PI3K inhibitors, many examples of which are in clinical trials for cancer, 
may offer a more specific targeted therapy.   
In conclusion, we report that a subset of patients with diffuse, megalencephalic forms of 
PIK3CA-related segmental overgrowth and MPPH exhibit severe insulin-independent hypoketotic 
hypoglycaemia.  This metabolic phenocopy of hypoglycaemia driven by genetic AKT2 activation 
is not seen in patients with extreme regional adipose or muscular overgrowth associated with “hot 
spot” activating PIK3CA mutations, suggesting that diffuse mutation carriage is more important 
than the degree of PI3K activation in determining the phenotype. We suggest that endocrinologists 
should be alert to the possibility of syndromic PI3K-related overgrowth when evaluating infants 
with hypoinsulinaemic hypoketotic hypoglycaemia, or with equivocal biochemical testing for 
congenital hyperinsulinism, and that they should understand the challenges of testing for a mosaic 
genetic disorder.  Prior knowledge and our cellular studies suggest that mTOR inhibitors may offer 
therapeutic benefit, and are worthy of clinical study.   
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Figure legends 
Figure 1: Schematic overview of INSR/PI3K/AKT signalling, showing known monogenic 
disorders.  Asterisks (*) denote mutations described in this report.  Abbreviations: GoF – gain of 
function, LoF – loss of function 
 
Figure 2: Syndromic features of patients 1 and 3.  A) Image of patient 1 at one month old 
demonstrating macrocephaly, facial hyperaemia and mildly asymmetric overgrowth.  B) Cutaneous 
syndactyly between the second and third toe on the right foot of P1.  C) Image of P1 at age 27 
months demonstrating macrocephaly, obesity and overgrowth.  D-E) Head and facial features of P3 
at 27 months showing macrocephaly, hypertrichosis, coarse facial appearance.  F) Deep palmar 
creases and excess skin in P3 
 
Figure 3: Mutations in PI3K-Associated Genes in Patients 1 to 3. A) Sanger sequencing 
showing de novo PIK3CA c.2176G>A mutation in patient 1 at 24-42 % in all tissues available for 
DNA testing. B) Schematic showing locations of the three PI3 kinase mutations associated with 
hypoglycaemia. Abbreviations used: p85 BD – p85 binding domain, RBD – Ras binding domain, 
SH2/3 – SRC Homology 2/3, BH – breakpoint cluster homologue, P – Proline rich domain, PH – 
Phox homology domain 
 
Figure 4:  Signalling Downstream from Phosphatidylinositol-3-kinase in dermal fibroblasts 
from Patient 1.  AKT phosphorylation at Thr308/309 (A) or Ser473/474 (B) was determined by 
ELISA.  Percentages in columns indicate the mutation burden in the cells.  Data represent pooled, 
normalised results from three independent experiments plotted as mean ± SEM.  One-way 
ANOVA and post hoc Dunnett’s test were used to assess significance.  Insulin stimulation is 
shown for illustration only and was excluded from this statistical analysis.  C) Immunoblotting for 
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total AKT (1/2/3) from samples used for ELISA (A-B). Representative blot from one of three 
independent replicates.  D-E) AKT Ser473/474 phosphorylation following 72 hours of Sirolimus 
treatment was quantified using ELISA and normalised to AKT expression determined by 
immunoblotting.  E) dermal fibroblasts from P21; F) dermal fibroblasts from P7.  Results represent 
mean ± SEM of three independent replicates.  DMSO on its own did not result in a change in 
phosphorylation (data not shown).  Statistical analysis was performed as one experiment and 
separate graphs are plotted for clarity only.  A two-way ANOVA was performed and followed by 
a post hoc Dunnett’s test comparing all patients to the same control cell line.  *: p<0.05, **: 
p<0.01, ***: p<0.001, ****: p<0.0001 
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 Table 1 – Summary of clinical syndromic features of patients 1-3 
 
Patient 1 Patient 2 Patient 3 
Age, years 5 2 2 
Sex Female Male Male 
Birth weight, kg 3.23 (+2.0 SD) 4.340 (+6.8 SD) 3.98 (+0.33 SD) 
Birth length, cm 52 (+1.5 SD) 53 (+1.66 SD) N/A 
Head circumference, 
cm 
37.5 (+2.3 SD) 41 (+5.14 SD) N/A 
CNS Features 
Megalencephaly 
Arnold-Chiari 
malformation 
Hydrocephalus 
Megalencephaly 
Arnold-Chiari 
malformation 
Polymicrogyria 
Hydrocephalus 
Megalencephaly  
Polymicrogyria 
Hydrocephalus 
Seizures Yes Yes Yes 
Poly-/syndactyly Yes Yes No 
Vascular Anomalies 
Hyperaemia of face 
Dorsal 
haemangioma 
Cutis marmorata 
Lower lip angioma 
Head and neck 
lymphatic 
malformations 
No 
Developmental delay Yes, severe Yes Yes, severe 
Hypotonia Yes Yes Yes 
Additional features 
Diastasis recti 
 Recurrent 
infections 
Rhizomelia 
Laryngomalacia 
Gastroesophageal 
reflux 
Coarse Facial 
Appearance 
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Table 2 – Representative biochemical profiles of patients 1-3.  Values marked with an asterisk (*) 
were determined during hypoglycaemia, **cut-offs for differentiation between hypoketotic and 
physiologic/ketotic response to hypoglycaemia. §A normal response to glucagon was defined as a rise 
in plasma glucose rose by at least 1.7 mmol/l following an intramuscular injection of at least 20 µg/kg 
glucagon. $Glucose infusion rates were not titrated to the minimum requirement.  ND – Not 
determined.  CHI - congenital hyperinsulinism 
 
Patient 1 Patient 2 Patient 3 
Reference 
range 
Age 9 months 4 days 15 months  
Glucose (mmol/l)* 2.5 2.7  1.9 3.9-5.5 
Insulin (pmol/l)* 
Not 
detectible 
Not 
detectible 
Not 
detectible 
<14 
C-peptide (nmol/l)* 0.05 0.2 0.227 <0.166** 
Urine ketones* Negative Negative Negative NA 
β-hydroxybutyrate 
(mmol/l)* 
0.024 ND 0.03 >1.8** 
Free fatty acids (µmol/l)* 138 
“Not 
elevated” 
153 
<720** 
Cortisol (nmol/l)* 993 464 323 >497 
Growth hormone (µg/l)* 7.5 4.7 8.3 >5 
Branched chain amino acids Normal Normal Normal N/A 
Glucagon stimulation test
$ 
Normal Normal Normal See legend 
Glucose infusion rate to 
maintain euglycaemia 
(mg/kg/min) 
2.4 14$ 13$ 
>8 in CHI 
in infancy 
Triglyceride (mmol/l) 1.1 1.1 1.0 <1.7 
IGF1 (ng/ml) <25 <25 <25 
F: 36-170 
M: 27-113 
IGFBP3 (µg/ml) 0.9 0.94 0.93 0.8-1.9 
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Table 3 – Genetic diagnosis and biochemical profile following an overnight fast in patients with PROS.  NR = Normal Range.  CLOVES - Congenital 
lipomatous overgrowth with vascular, epidermal, and skeletal anomalies; FAH – Fibroadipose hyperplasia; MO = muscle overgrowth; KTS - Klippel-Trenaunay 
syndrome; MD = macrodactyly; MCAP – Macrocephaly and capillary malformation syndrome; ND – not determined.  BMI-specific reference ranges for 
adiponectin in females – <25 kg/m
2
: 4.4-17.7 mg/ml; 30-35 kg/m2: 2.6-14.9 mg/ml; >35 kg/m
2
: 2.6-17.1 mg/ml.  Adiponectin reference in males – <25 kg/m
2
: 
2.6-12.6 mg/ml; 25-30 kg/m2: 2.4-10.6 mg/ml.  BMI-specific reference ranges for leptin in females – <25 kg/m2: 2.4-24.4 ng/ml; 25-30 kg/m2: 8.6-38.9 ng/ml; 
>35 kg/m2: 22.7-113.6 ng/ml.  Leptin reference in males – <25 kg/m2: 0.4-8.3 ng/ml; 25-30 kg/m2: 1.5-13.0 ng/ml.  Age-specific IGF-1 references ranges in 
females – 9-11 years: 87-396 ng/ml; 16-20 years: 266-467 ng/ml; 21-24 years: 148-330 ng/ml; 25-40 years: 123-304 ng/ml. IGF-1 reference ranges in males – 2-
60 months: 27-113 ng/ml; 12-15 years: 115-495 ng/ml; 21-24 years: 186-397 ng/ml; 25-40 years: 124-300 ng/ml; 41-50 years: 89-239ü ng/ml.  
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ID Sex 
Age, 
years Syndrome 
Site of 
overgro
wth 
B.M.I., 
kg/m
2 
or 
*Z-score 
Fat 
mass, 
% 
PIK3CA 
mutation 
Glucose, 
mmol/l 
Insulin, 
pmol/l 
HbA1c, 
mmol/mol 
Adiponectin, 
mg/l 
Leptin, 
µg/l 
IGF1, 
ng/ml 
NR 
 
3.9-5.5 0-60 30-48 see legend 
see 
legend see legend  
P4 M 48 CLOVES 
L foot 26.7 13 C420R 4.0 11 40 23.2 ND 76 
P5 M 29 CLOVES 
L leg & 
trunk 25.7 23 E545K 4.5 27 34 3.8 5.7 163 
P6 M 15 CLOVES 
R thorax -1.6* 19 E542K 6.2 165 ND 17.3 1.8 119 
P7 F 37 FAH 
Both legs 55 54 H1047L 3.9 13 36 16.9 166 141 
P8 F 31 FAH 
R arm 32.5 46 H1047L 4.7 ND ND ND ND 221 
P9 F 34 FAH 
L leg 32.7 47 H1047R 4.7 217 43 1.5 45.5 141 
P10 F 9 FAH 
L leg >+3* 29 H1047R 4.8 42 36 ND ND 122 
P11 F 22 MO 
Both 
arms 21.9 32 H1047R 4.7 31 ND 6.3 6.6 242 
P12 M 34 KTS 
L leg 27.8 38 V346insK 4.3 29 38 ND 16 168 
P13 F 40 MD 
L hand 32.8 57 H1047R 4.5 73  37 ND ND ND 
P14 F 39 MD 
2 R 
fingers 25 40 
M1043_ 
N1044delinsIY 4.7 41 33 7.4 13.5 176 
   
 
        
 
P15 F 35 MCAP 
Diffuse 34.9 38 G118D 5.1 31 40 5.1 33.3 145 
P16 M 29 MCAP 
Diffuse 27.1 23 E81K 5.2 31 38 3.9 4.1 158 
P17 F 18 MCAP Diffuse 23.6 43 E81K 5.1 80 35 8.6 31.4 382 
P18 F 21 MCAP 
Diffuse 43 52 G914R 5.4 51 36 5.1 ND 85 
P19 M 1.5 MCAP 
Diffuse ND ND R88Q 5.1 <3 48 ND ND <25 
P20 M 21 MCAP 
Diffuse 23.9 44 E726K 3.9 7 ND 6.6 2 28 
P21 M 3 MCAP 
Diffuse +1* 43 R93Q 4.3 18 ND ND ND 60 
P22 M 12 MCAP 
Diffuse ND ND D350G 3.9 <14 ND ND ND 80 
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